



BOARD OF SUPERVISORS  
AGENDA LETTER

Agenda Number:

Clerk of the Board of Supervisors  
105 E. Anapamu Street, Suite 407  
Santa Barbara, CA 93101  
(805) 568-2240

Submitted on:  
(COB Stamp)

Department Name: Behavioral Wellness  
Department No.: 043  
Agenda Date: April 21, 2026  
Placement: Administrative Agenda  
Estimated Time: N/A  
Continued Item: No  
If Yes, date from:  
Vote Required: Majority

---

**TO:** Board of Supervisors  
**FROM:** Department Director: Antonette Navarro, LMFT, Director  
Department of Behavioral Wellness  
Contact: Melissa Wilkins, MPH, CADC-II, CCPS, Branch Chief  
Department of Behavioral Wellness  
**SUBJECT:** Third Amendment to the Services Agreement (BC 23-074) with Aegis Treatment Centers, LLC for Drug Medi-Cal Organized Delivery System (DMS-ODS) Narcotic and Opioid Treatment Program Services for Fiscal Year (FY) 2023-27

---

**County Counsel Concurrence**

As to form: Yes

**Other Concurrence:** Risk Management

As to form: Yes

**Auditor-Controller Concurrence**

As to form: Yes

**Recommended Actions:**

That the Board of Supervisors:

- a) Approve, ratify, and authorize the Chair to execute a Third Amendment to the Agreement for Services of Independent Contractor (BC 23-074) with Aegis Treatment Centers, LLC (Aegis) (not a local vendor) to update certain standard provisions for compliance with State and federal requirements and to clarify the obligations of the parties, update the Schedule of Rates and Contract Maximum, update the Entity Rates and Codes by Service Type, amend the foot note in the performance goals, outcomes, and measures, and increase the contract amount by \$578,400 for a revised total maximum contract amount not to exceed \$25,154,100, inclusive of \$5,325,900 for fiscal year (FY) 2023-24, \$6,416,600 for FY 2024-25, \$6,332,500 for FY 2025-26, and \$7,079,100 for FY 2026-27, resulting in no change to the contract term of July 1, 2023 through June 30, 2027; and
- b) Determine that the above-recommended action is not a project that is subject to environmental review under the California Environmental Quality Act (CEQA), pursuant to CEQA Guidelines section 15378(b)(4), finding that the action is governmental funding

mechanisms and/or fiscal activities that will not result in direct or indirect physical changes in the environment.

**Summary Text:**

The Board of Supervisors is requested to authorize the Chair to execute the Third Amendment to the Agreement with Aegis Treatment Centers, LLC (Aegis) to ensure the continued delivery of Narcotic and Opioid Treatment Program Services by updating certain State and federal terms to ensure compliance with new and updated provisions, and updating the rates and codes by service type to include two (2) additional Drug Medi-Cal Organized Delivery System (DMC-ODS) approved formularies – Vivitrol (injectable naltrexone) and Sublocade (injectable buprenorphine) – for opioid use disorder (OUD) treatment. These amendments first result in a decrease of \$84,100 for FY 2025-26, followed by an increase of \$662,500 for FY 2026-27 to the total maximum contract amount. These changes do not affect the contract term of July 1, 2023 through June 30, 2027.

Approval of the recommended actions will allow the Behavioral Wellness Department (BWell) to continue to fund these DMS-ODS Narcotic and Opioid Treatment Program Services.

**Discussion:**

Aegis provides Narcotic Treatment Program (NTP)/Opioid Treatment Program (OTP) services to adult members (ages 18 and over) as well as adolescent members (under the age of 21) with Opioid Use Disorders (OUD). These services are categorized by the American Society of Addiction Medicine (ASAM) as Opioid Treatment Services.

BWell now requests to amend the existing agreement with Aegis to update certain standard provisions for compliance with State and federal requirements, update general Alcohol and Drug Program (ADP) and financial provisions. With this amendment, the contractor's billing codes in SmartCare are being updated to include two (2) additional Drug Medi-Cal Organized Delivery System (DMC-ODS) approved formularies for the treatment of OUD, which are Naltrexone Injectable (Vivitrol) and Buprenorphine Injectable (Sublocade). Both Vivitrol and Sublocade are now included in the DMC-ODS formulary for OUD treatment. The addition of these medications allows Aegis to offer injectable medications and will improve continuity of care for individuals transitioning from jail settings who are receiving injectable medications for OUD.

Due to adding additional DMC-ODS approved formularies, the contract amount increases by \$578,400 for a revised total of \$25,154,100. This amendment will result in no change to the term of the agreement.

**Background:**

BWell provides a continuum of mental health and substance use disorder services to Santa Barbara County residents, in part, through contracted providers including Community-Based Organizations (CBOs). On July 18, 2023, the Board of Supervisors approved the Agreement for Services with Aegis Treatment Centers, LLC, for DMC-ODS services for FY 2023-27 (BC 23-074).

NTP/OTP are pharmacological and nonpharmacological treatment modalities supervised by board-certified medical doctors. NTP/OTP services include opioid agonist medications such as methadone and buprenorphine, and opioid antagonist medications such as naltrexone. NTP/OTP also includes the following service components: assessment, care coordination, clinician consultation, counseling (individual and group), family therapy, medical psychotherapy, medication services, Medication-Assisted Treatment (MAT) for OUD, MAT for Alcohol Use Disorders (AUD) and other non-opioid Substance Use Disorder (SUD), peer support, patient education, recovery services, and SUD crisis intervention services counseling services.

On December 3, 2024, the Board of Supervisors approved a first amendment to the agreement to amend the terms concerning Overdose Prevention Training and Medical Necessity Determination, add the inclusion of the new Medication Unit located in Lompoc, and increase the contract by \$1,629,000, for a revised total contract amount of \$21,702,600, for the period of July 1, 2023 through June 30, 2027.

On June 10, 2025, the Board of Supervisors approved a second amendment to the agreement to update certain federal and State terms to be in compliance with federal and State regulations, to update the entity rates and codes by services type for Outpatient Non-Medical Direct Services and Outpatient Medical Prescriber Services, and to increase the contract amount by \$2,873,100 due to the need for services that was higher than originally anticipated, for a revised total maximum contract amount of \$24,575,700, for the period of July 1, 2023 through June 30, 2027.

With this third amendment, certain federal and State terms are being updated and the entity rates and codes by services type to ensure that injectable medications are included in the services that Aegis can provide.

### **Performance Measure:**

The agreement with Aegis identifies program goals, outcomes and measures to monitor program implementation and improve DMC-ODS efficiency in Exhibit E. The program goals are to support successful SUD treatment and recovery through:

#### **Opioid Treatment Program (OTP) measures**

- Members initiating treatment, with a goal of 90% treatment initiation;
- Members engaging in treatment, with a goal of 85% treatment engagement;
- Members retained in treatment for a year, with a goal of 30% retained;
- Members successfully completed treatment, with a goal of 25% successful completion; and
- Members abstinent from substances other than the prescribed narcotic replacement, with a goal of 75% abstinence for those in treatment 6 months or more.

#### **Perinatal measures**

- For Perinatal members, 100% drug-free births;
- Perinatal members abstinent at discharge from substances other the prescribed narcotic replacement, with a goal of 100%; and
- For Perinatal members, 70% successful completion.

### **Contract Renewals:**

#### Performance Outcomes

The following summaries highlight key data points for the 8 separate measures available for the entire FY 2024-25:

- **Opioid Treatment Program** – During FY 2024-25, they served an average of 937 clients per quarter, with an average of 174 new enrollments per quarter and an average of 155 discharges per quarter. Across Santa Barbara, Santa Maria and Lompoc adult programs, 3 out of the 5 goals were met. The 2 instances where they did not meet the goals were clients engaged in treatment where the goal was 85% and the quarterly average was 74% and the second goal was clients retained in treatment for 1 year with a goal of 30% and the quarterly average was 27% (nearly /functionally met).

- Perinatal** – During FY 2024-25, they served an average of 9 clients per quarter with an average of 1.3 discharges. The program has 3 identified goals. Drug free births with a goal of 100%, the quarterly average was 77%. A goal of 100% of clients abstinent at discharge with the quarterly average of 50%. Lastly, a goal of 70% of clients who successfully completed treatment, with a quarterly average of 50%. Of note, the sample size for this outcome data is small, which makes the goal percentages difficult to reach.

The following summaries highlight key data points for the 8 separate measures available for Q1 of FY 2025-26:

- Opioid Treatment Program** - During Q1 of FY 2025-26, they served 960 clients with 188 new enrollments and 156 discharges. Across Santa Barbara, Santa Maria and Lompoc adult programs, they are meeting 3 out of the 5 goals. The 2 instances where they did not meet the goals are clients engaged in treatment where the goal was 85% and Q1 was 73% and the second is clients successfully completed treatment with the goal of 25% and Q1 was 12%. Discharge guidance was provided to Aegis by BWell in October of 2025, therefore the goal for clients who successfully complete treatment should increase with the new discharge reason guidance.
- Perinatal** – During Q1 of FY 2025-26, they served 12 clients and had 3 discharges. The program has 3 identified goals. 1/3 were met in Q1: drug free births, with a goal of 100%, was 100%. A goal of 100% of clients abstinent at discharge was 67%. A goal of 70% of clients successfully completed treatment, with Q1 average of 0%. Again, the sample size for this outcome data is small, which makes the goal percentages difficult to reach.

**Fiscal and Facilities Impacts:**

Budgeted: Yes

The above-referenced agreement is funded with federal funds. There is no impact to the General Fund. Funding for this contract was included in the Adopted Budgets for FY 2023-24, FY 2024-25, and FY 2025-26. Funding will be included in BWell’s proposed budget for FY 2026-27 but remains contingent on the Board of Supervisors’ approval.

With the transition to California Advancing and Innovating Medi-Cal (CalAIM) Payment Reform, the fee-for-service portion of the contract will be funded with Medi-Cal Patient Revenue which primarily consists of federal funds. The amount of federal funds is contingent on the member’s aid code, and the State-issued rate for the service.

An increase to the contract is necessary to accommodate greater than anticipated service demand.

**Fiscal Analysis:**

Funding Source	FY 2023-24	FY 2024-25	FY 2025-26	FY 2026-27	Total
Medi-Cal Patient Revenue	\$5,325,900	\$6,416,600	\$6,332,500	\$7,079,100	<b>\$25,154,100</b>
<b>Total</b>	<b>\$5,325,900</b>	<b>\$6,416,600</b>	<b>\$6,332,500</b>	<b>\$7,079,100</b>	<b>\$25,154,100</b>

**Special Instructions:**

Please email one (1) complete, executed copy of the above Amendment and one (1) Minute Order to [sarriaga@sbcbswell.org](mailto:sarriaga@sbcbswell.org) and to [bwelcontractsstaff@sbcbswell.org](mailto:bwelcontractsstaff@sbcbswell.org).

**Attachments:**

**Attachment A** – Aegis Treatment Centers FY 2023-27 Board Contract Third Amendment

**Attachment B** – Aegis Treatment Centers FY 2023-27 Board Contract Second Amendment

**Attachment C** – Aegis Treatment Centers FY 2023-27 Board Contract First Amendment

**Attachment D** – Aegis Treatment Centers FY 2023-27 Board Contract BC 23-074 executed

**Contact Information:**

Svetlana Arriaga

Contracts Analyst

[sarriaga@sbcbswell.org](mailto:sarriaga@sbcbswell.org)